PCM
OKUR

Prelude Capital Management’s OnKure Therapeutics OKUR Stock Holding History

Prelude Capital Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,722
Closed -$28.6K – 1556
2024
Q1 		$28.6K Buy
+1,722
New +$28.4K ﹤0.01% 1272
2023
Q4 		– Sell
-1,480
Closed -$113K – 1409
2023
Q3 		$113K Hold
1,480
– – 0.01% 979
2023
Q2 		$97.1K Hold
1,480
– – 0.01% 936
2023
Q1 		$88.5K Buy
+1,480
New +$53.6K 0.01% 962

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Prelude Capital Management's OKUR Position: Q2 2024 in Review

Prelude Capital Management sold out of OnKure Therapeutics (OKUR) in Q2 2024, closing a stake of 1,722 shares — an estimated $28.6K sold.

Prelude Capital Management first reported a position in OKUR in Q1 2023 and held it in 4 quarters. The position peaked at $113K in Q3 2023. 66 funds tracked by Wall St. Rank hold OKUR as of Q2 2024.

  • Prelude Capital Management reported no remaining OnKure Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Prelude Capital Management sold 1,722 OnKure Therapeutics shares in Q2 2024, an estimated $28.6K.
  • Prelude Capital Management first reported a position in OnKure Therapeutics in Q1 2023 and held it in 4 quarters.
  • Prelude Capital Management's OnKure Therapeutics position peaked at $113K in Q3 2023.
  • 66 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2024.

Based on Prelude Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.